<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">SAQUINAVIR MESYLATE <img border="0" src="../images/pr.gif"/></span><br/>(sa-quin'a-vir mes'y-late)<br/><span class="topboxtradename">Invirase<br/></span><b>Classifications:</b> <span class="classification">antiretroviral agent</span>; <span class="classification">protease inhibitor</span><br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p><b></b> 200 mg capsules; 500 mg tablet
      </p>
<h1><a name="action">Actions</a></h1>
<p>Synthetic peptide that inhibits the activity of HIV protease and prevents the cleavage of viral polyproteins essential for
         the maturation of HIV.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Indicated by reduced viral load (decreased number of RNA copies), and increased number of T helper CD4 cells.</p>
<h1><a name="uses">Uses</a></h1>
<p>Advanced HIV infection, usually in combination with zidovudine or zalcitabine.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Significant hypersensitivity to saquinavir; concurrent administration with lovastatin, simvastatin, antimicrobial resistance
         to other protease inhibitors, monotherapy, lactation.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Hepatic insufficiency; hepatitis B or C; diabetes mellitus, diabetic ketoacidosis, hemophilia A or B, pregnancy (category
         B). Safety and effectiveness in HIV-infected children 
      </p><h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">HIV</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> Invirase 600 mg (3 <small>x</small> 200 mg) t.i.d. taken 2 h after a full meal; Fortovase 1200 mg (6 <small>x</small> 200
               mg) t.i.d. with meals; or 1000 mg b.i.d. with ritonavir 100 mg b.i.d. <br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give with or up to 2 h after a full meal to ensure adequate absorption and bioavailability.</li>
<li>Do not administer to anyone taking rifampin or rifabutin because these drugs significantly decrease the plasma level of saquinavir.</li>
<li>Store Invirase at 15°30° C (59°86° F) in tightly closed bottle. Store Fortovase in refrigerator.
            Capsules are stable for 3 mo at room temperature <img src="../images/special/lesserorequal.gif"/>25° C (<img src="../images/special/lesserorequal.gif"/>77°
            F).
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Headache, paresthesia, numbness, dizziness, peripheral neuropathy, ataxia, confusion, convulsions, hyperreflexia, hyporeflexia,
      tremor, agitation, amnesia, anxiety, depression, excessive dreaming, hallucinations, euphoria, irritability, lethargy, somnolence. <span class="typehead">CV:</span> Chest pain, hypertension, hypotension, syncope. <span class="typehead">Endocrine:</span> Dehydration, hyperglycemia, diabetes, weight changes.  <span class="typehead">Hematologic:</span> Anemia, splenomegaly, thrombocytopenia, <span class="speceff-life">pancytopenia</span>. <span class="typehead">GI:</span>
<span class="speceff-common">Nausea, diarrhea, abdominal discomfort,</span> dyspepsia, mucosal damage, change in appetite, dry mouth.  <span class="typehead">Skin:</span> Rash, pruritus, acne, erythema, seborrhea, hair changes, photosensitivity, skin ulceration, dry skin. <span class="typehead">Body as a Whole:</span> Myalgia, allergic reaction. <span class="typehead">Respiratory:</span> Bronchitis, cough, dyspnea, epistaxis, hemoptysis, laryngitis, rhinitis. <span class="typehead">Special Senses:</span> Xerophthalmia, ear ache, taste alterations, tinnitus, visual disturbances. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Rifampin,</b>
<b>rifabutin</b> significantly decrease <b>saquinavir</b> levels. <b>Phenobarbital,</b>
<b>phenytoin,</b>
<b>dexamethasone,</b>
<b>carbamazepine</b> may also reduce <b>saquinavir</b> levels. <b>Saquinavir</b> levels may be increased by <b>delavirdine,</b>
<b>ketoconazole,</b>
<b>ritonavir,</b>
<b>clarithromycin,</b>
<b>indinavir.</b> May increase serum levels of <b>triazolam,</b>
<b>midazolam,</b>
<span class="classification">ergot derivatives</span>, <b>nelfinavir,</b>
<b>sildenafil.</b> May significantly increase <b>simvastatin</b> levels and toxicity; may increase risk of <b>ergotamine</b> toxicity of <b>dihydroergotamine, ergotamine.</b>
<span class="typehead">Herbal:</span>
<b>St. John's wort</b>, garlic may decrease <span class="classification">antiretroviral</span> activity. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Rapidly absorbed from GI tract; only 4% reaches systemic circulation; food significantly increases bioavailability. <span class="typehead">Distribution:</span> 98% protein bound. <span class="typehead">Metabolism:</span> Metabolized in liver by cytochrome P450, first-pass metabolism. <span class="typehead">Elimination:</span> Excreted primarily in feces (&gt;80%). Half life: 13 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Monitor serum electrolytes, CBC with differential, liver function, blood glucose and HbA<sub>1C</sub>, CPK, and serum amylase prior to initiating therapy and periodically thereafter.
         </li>
<li>Monitor for and report S&amp;S of peripheral neuropathy.</li>
<li>Assess for buccal mucosa ulceration or other distressing GI S&amp;S.</li>
<li>Monitor weight periodically.</li>
<li>Monitor for toxicity if any of the following drugs is used concomitantly: calcium channel blockers, clindamycin, dapsone,
            quinidine, triazolam, or simvastatin.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Take drug within 2 h of a full meal.</li>
<li>Be aware of all drugs which should not be taken concurrently with saquinavir.</li>
<li>Be aware that saquinavir is not a cure for HIV infection and that its long-term effects are unknown.</li>
<li>Report any distressing adverse effects to physician.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>